SCHEMBL1959161

SCHEMBL1959161

CSc1ccc(C(O)(CC2CCCC2)c2cc3cc(F)cnc3n2S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.33
CHRM3 P20309 1/20 0.33
HTR6 P50406 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
PKM P14618 1/20 0.31
APOBEC3A P31941 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
CASP3 P42574 2/20 0.31
CASP7 P55210 2/20 0.31
TP53 P04637 2/20 0.31
MAPT P10636 2/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
FKBP1A P62942 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.30
ABHD6 Q9BV23 1/20 0.30
DAGLA Q9Y4D2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1961245 0.98 CHRM3 (0.33) GCKCHRM3HTR6MEN1KMT2A
SCHEMBL1960340 0.90 GCK (0.36) GCKCHRM3
SCHEMBL1959597 0.89 CCR2 (0.36) GCKCHRM3
SCHEMBL1962937 0.88 GCK (0.40) GCKCHRM3HTR6MEN1KMT2A
SCHEMBL1960337 0.87 GCK (0.33) GCKCHRM3HTR6
SCHEMBL2054075 0.86 NR3C2 (0.32) GCKCHRM3ALDH1A1
SCHEMBL1962132 0.86 GCK (0.32) GCKCHRM3HTR6
SCHEMBL27889561 0.85 FKBP1A (0.32) CHRM3FKBP1A
SCHEMBL27873097 0.85 NR1H3 (0.30) CHRM3FKBP1A
SCHEMBL1961501 0.77 GCK (0.45) GCKCHRM3PKMSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GCK 1/4885CHRM3 3330/4885HTR6 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.